CNMD Share Price | CONMED Corp. Stock Analysis & Recommendation

Q: How big is CONMED Corp.?

As of Jun 18, CONMED Corp. has a market capitalization of 1,724.14 million, categorizing it as a Small Cap company.As of Jun 18, the company reported net sales of 1,310.50 million and a net profit of 118.75 million for the latest four quarters.As of Dec 24, the balance sheet shows shareholder's funds of 962.68 million and total assets of 2,306.25 million.

Q: What does CONMED Corp. do?

Overview: CONMED Corporation is a medical technology company engaged in the development, manufacturing, and sale of surgical devices and related equipment, primarily for minimally invasive procedures, within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Sales: 319 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025) Market cap: USD 1,724.14 Million (Small Cap) Key Metrics: P/E: 21.00 Dividend Yield: 142.63% Debt Equity: 0.88 Return on Equity: 9.11% Price to Book: 1.76 Contact Details: Address: 525 French Road, UTICA NY: 13502 Tel: ['1 315 7978375', '1 315 6243317'] Fax: 1 302 6555049

Q: Is CONMED Corp. overvalued or undervalued?

As of 30 June 2025, CONMED Corp. has moved from a fair to attractive valuation grade. The company appears to be undervalued, with a P/E ratio of 21, an EV to EBITDA of 13.82, and a Price to Book Value of 1.92. In comparison to peers, Globus Medical, Inc. has a P/E of 18.37, while Sanmina Corp. shows a much higher P/E of 39.80, indicating that CONMED may offer better value relative to these competitors.However, it's important to note that CONMED has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -24.87% compared to the S&P 500's 12.22%. This significant underperformance may raise concerns about the company's growth prospects despite its attractive valuation metrics.

Q: Is CONMED Corp. technically bullish or bearish?

As of 1 August 2025, the technical trend for CONMED Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but remains bearish on the monthly. The RSI indicates no signal on both weekly and monthly timeframes. Bollinger Bands and moving averages are bearish, while KST shows a mildly bullish signal weekly but is bearish monthly. Dow Theory presents a mildly bearish stance weekly and mildly bullish monthly. In terms of performance, CONMED has significantly underperformed the S&P 500 across all multi-period returns, with a year-to-date return of -24.87% compared to the S&P 500's 12.22%, and a one-year return of -32.35% against the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

868.36 k

Shareholding (Dec 2025)

FII

9.64%

Held by 119 FIIs

DII

20.34%

Held by 74 DIIs

Promoter

2.45%

How big is CONMED Corp.?

22-Jun-2025

As of Jun 18, CONMED Corp. has a market capitalization of $1.72 billion, with net sales of $1.31 billion and a net profit of $118.75 million over the latest four quarters. The balance sheet shows shareholder's funds of $962.68 million and total assets of $2.31 billion.

View full answer

What does CONMED Corp. do?

22-Jun-2025

CONMED Corporation is a medical technology company that develops and sells surgical devices for minimally invasive procedures. As of March 2025, it reported net sales of $319 million and a market cap of $1.72 billion.

View full answer

Is CONMED Corp. overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, CONMED Corp. is considered undervalued with a P/E ratio of 21 and an attractive valuation grade, but it has underperformed the S&P 500 with a year-to-date return of -24.87%, raising concerns about its growth prospects.

View full answer

Is CONMED Corp. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, CONMED Corp. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -24.87% versus the S&P's 12.22%.

View full answer

Compare CONMED Corp. with Similar Stocks

Integra LifeSciences Holdings Corp.Sanmina Corp.Glaukos Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 18.38% of over the last 5 years

The company has declared negative results in Mar'2025 after 3 consecutive positive quarters

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,231 Million (Small Cap)

P/E

18.00

Industry P/E

Dividend Yield

99.91%

Debt Equity

0.78

Return on Equity

6.65%

Price to Book

1.19

Revenue and Profits:

Net Sales:

373 Million

(Quarterly Results - Dec 2025)

Net Profit:

17 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.02%

6 Months

-30.11%

1 Year

-40.7%

2 Years

-52.96%

3 Years

-60.16%

4 Years

-75.25%

5 Years

-70.76%

CONMED Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.82%

EBIT Growth (5y)

12.68%

EBIT to Interest (avg)

3.03

Debt to EBITDA (avg)

5.39

Net Debt to Equity (avg)

0.88

Sales to Capital Employed (avg)

0.69

Tax Ratio

18.26%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

6.55%

ROE (avg)

7.82%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.19

EV to EBIT

14.58

EV to EBITDA

10.29

EV to Capital Employed

1.11

EV to Sales

1.48

PEG Ratio

Dividend Yield

99.91%

ROCE (Latest)

7.60%

ROE (Latest)

6.65%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 93 Schemes (67.48%)

Foreign Institutions

Held by 119 Foreign Institutions (9.64%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 10.31% vs -1.28% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 475.86% vs -86.45% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "373.50",
          "val2": "338.60",
          "chgp": "10.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "85.70",
          "val2": "32.50",
          "chgp": "163.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.40",
          "val2": "7.60",
          "chgp": "-2.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-30.30",
          "val2": "-7.00",
          "chgp": "-332.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.70",
          "val2": "2.90",
          "chgp": "475.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "179.10%",
          "val2": "57.30%",
          "chgp": "12.18%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 5.51% vs 4.97% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -64.43% vs 105.27% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,374.50",
          "val2": "1,302.70",
          "chgp": "5.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "193.50",
          "val2": "215.50",
          "chgp": "-10.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "31.10",
          "val2": "37.30",
          "chgp": "-16.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-38.30",
          "val2": "30.70",
          "chgp": "-224.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.10",
          "val2": "132.40",
          "chgp": "-64.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "102.70%",
          "val2": "126.10%",
          "chgp": "-2.34%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

373.50

338.60

10.31%

Operating Profit (PBDIT) excl Other Income

85.70

32.50

163.69%

Interest

7.40

7.60

-2.63%

Exceptional Items

-30.30

-7.00

-332.86%

Consolidate Net Profit

16.70

2.90

475.86%

Operating Profit Margin (Excl OI)

179.10%

57.30%

12.18%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 10.31% vs -1.28% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 475.86% vs -86.45% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,374.50

1,302.70

5.51%

Operating Profit (PBDIT) excl Other Income

193.50

215.50

-10.21%

Interest

31.10

37.30

-16.62%

Exceptional Items

-38.30

30.70

-224.76%

Consolidate Net Profit

47.10

132.40

-64.43%

Operating Profit Margin (Excl OI)

102.70%

126.10%

-2.34%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 5.51% vs 4.97% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -64.43% vs 105.27% in Dec 2024

All Annual Results

Company CV

About CONMED Corp.

CONMED Corp.

Pharmaceuticals & Biotechnology

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery and general surgery.

Company Coordinates

Company Details

525 French Road , UTICA NY : 13502

Tel: 1 315 79783751 315 6243317

Registrar Details